The gene therapy sector continues to garner substantial investment and scientific breakthroughs. Kriya Therapeutics secured $313 million to advance a pipeline of gene therapies targeting ophthalmic, metabolic, and neurological diseases using AAV vectors despite concerns over vector-related toxicities. Concurrently, LB Pharmaceuticals prepares an IPO linked to an antipsychotic therapy nearing phase III trials. Additionally, Develop Health raised $14.3 million to streamline prior authorization, reflecting fintech integration in healthcare.